Placebo News and Research

RSS

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

While several clinical trials have demonstrated that maintenance therapy with lenalidomide reduces the risk of disease progression in patients with multiple myeloma, there have been no definitive results regarding overall survival.

6 Jun 2016

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

Salsalate has no greater effect than placebo on the progression of coronary artery plaque, show the findings of the randomised TINSAL-CVD trial.

3 Jun 2016

Alcoholic individuals may form stronger memory associations with alcohol-related environmental stimuli

Drug-cue associations can have a powerful influence over individuals with drug and alcohol use disorders, often leading to relapse in those attempting to stay abstinent. Few studies have investigated how drugs affect learning or memory for drug-associated stimuli in humans.

2 Jun 2016

$CD34+ cell therapy improves angina frequency in no option patients with class III/IV angina refractory$

CD34+ cell therapy improves angina frequency in no option patients with class III/IV angina refractory

A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34 -- a member of a family of proteins that have an impact on vascular-associated tissue -- cells had a significant reduction in angina frequency over patients who received placebo.

2 Jun 2016

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

On Friday, May 27, the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.

1 Jun 2016

Additional drug treatment options to prevent migraine may offer hope to sufferers

Preventing or shortening the duration of migraine attacks - established drug treatment options and those that could shape future therapies were discussed at the Congress of European Academy of Neurology in Copenhagen.

1 Jun 2016

Betrixaban scores near miss for extended thromboprophylaxis

Extended thromboprophylaxis with the direct factor Xa inhibitor betrixaban just fails to show superiority to standard treatment with enoxaparin in acutely ill medical patients.

1 Jun 2016

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago.

28 May 2016

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.

28 May 2016

Study explores how lighting impacts healthy food choices

Dining in dimly lit restaurants has been linked to eating slowly and ultimately eating less than in brighter restaurants, but does lighting also impact how healthfully we order?

27 May 2016

First clinical trial to study use of Chinese Herbal Medicines in treating RUTIs

Researchers at the University of Southampton are to study the use of Chinese Herbal Medicines in treating recurrent urinary tract infections (RUTIs), in the first clinical trial of its kind in the UK.

25 May 2016

Transplanted human stool may offer treatment hope for ulcerative colitis patients

Patients with ulcerative colitis (UC) may improve their symptoms with a transplantation of healthy stool from donors, according to Australian researchers. The findings were presented by Dr Sudarchan Paramsothy MD, a gastroenterologist from the University of New South Wales, Australia at the Digestive Disease Week conference in San Diego, California between the 21st to 24th May.

24 May 2016

Early aspirin benefits after minor stroke 'underestimated'

A meta-analysis of individual patient data has thrown light on the benefits of aspirin for secondary prevention in patients with ischaemic stroke.

19 May 2016

SUSTAIN study to test effect of high-dose selenium on recovery of cardiac surgery patients

Queen's University researcher Daren Heyland is leading a study that aims to reduce the risk of complications and improves recovery of cardiac surgery patients.

19 May 2016

High doses of vitamin D supplements could lead to fewer birth complications but reduce fertility

New research has established that high doses of vitamin D supplements can lead to fewer complications during childbirth but reduce a woman's chances of getting pregnant in the first place.

19 May 2016

Early high-dose rhEPO fails to improve neurodevelopment in very preterm infants

Very preterm infants do not gain protection against neurodevelopmental delay with early prophylactic high-dose recombinant human erythropoietin, researchers report.

19 May 2016

Melatonin can be of great value for elderly people suffering from hypertension

The older we get, the more likely our circadian rhythms are disrupted. For example, blood pressure (BP), not only tends to increase but as well become more irregular. Luckily, as we show in our research, melatonin helps to ameliorate both trends.

18 May 2016

Smokers who use novel nicotine inhaler twice as likely to quit smoking

A study by researchers at New Zealand's University of Otago, Wellington shows that smokers who used a nicotine inhaler were twice as likely to quit smoking as smokers using a placebo inhaler.

17 May 2016

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today.

17 May 2016

Pluristem completes enrollment in Phase II intermittent claudication trial

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.

16 May 2016

Placebo News and Research

Maintenance lenalidomide treatment improves overall survival in multiple myeloma patients

Neutral atherosclerosis trial highlights effectiveness of optimal medical therapy

Alcoholic individuals may form stronger memory associations with alcohol-related environmental stimuli

CD34+ cell therapy improves angina frequency in no option patients with class III/IV angina refractory

Ocaliva drug gets FDA approval for primary biliary cholangitis treatment

Additional drug treatment options to prevent migraine may offer hope to sufferers

Betrixaban scores near miss for extended thromboprophylaxis

Oncologists to present latest research findings at ASCO annual meeting

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

Study explores how lighting impacts healthy food choices

First clinical trial to study use of Chinese Herbal Medicines in treating RUTIs

Transplanted human stool may offer treatment hope for ulcerative colitis patients

Early aspirin benefits after minor stroke 'underestimated'

SUSTAIN study to test effect of high-dose selenium on recovery of cardiac surgery patients

High doses of vitamin D supplements could lead to fewer birth complications but reduce fertility

Early high-dose rhEPO fails to improve neurodevelopment in very preterm infants

Melatonin can be of great value for elderly people suffering from hypertension

Smokers who use novel nicotine inhaler twice as likely to quit smoking

Magic mushroom compound may offer potential new way for antidepressant research

Pluristem completes enrollment in Phase II intermittent claudication trial

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News